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Summary
Objectives: Invasive fungal infections caused by Lomentospora prolificans are associ-
ated with very high mortality rates and can be challenging to treat given pan-drug 
resistance to available antifungal agents. The objective of this study was to describe 
the clinical presentation and outcomes in a cohort of patients with invasive L prolifi-
cans infections.
Methods: We performed a retrospective review of medical records of patients with 
invasive L prolificans infection in the FungiScope® registry of rare invasive fungal in-
fections. Patients diagnosed between 01 January 2008 and 09 September 2019 were 
included in for analysis.
Results: The analysis included 41 patients with invasive L prolificans infection from 
eight different countries. Haematological/oncological malignancies were the most 
frequent underlying disease (66%), disseminated infection was frequent (61%), and 
the lung was the most commonly involved organ (44%). Most infections (59%) were 
breakthrough infections. Progression/deterioration/treatment failure was observed 
in 23/40 (58%) of patients receiving antifungal therapy. In total, 21/41 (51%) patients, 
and 77% of patients with underlying haematological/oncological malignancy, had a 
fatal outcome attributed to invasive fungal infection. Combination antifungal therapy 
was frequent (24/40) and associated with improved survival. In particular, treatment 
regimens including terbinafine were significantly associated with higher treatment 
success at final assessment (P = .012), with a positive trend observed for treatment 
regimens that included voriconazole (P = .054).
Conclusions: Lomentospora prolificans infections were associated with mortal-
ity rates of 77% and above in patients with underlying haematological/oncological 
malignancies and those with disseminated infections. While combination therapy is 
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1  | INTRODUC TION
Lomentospora prolificans are filamentous fungi commonly found in 
soil and polluted waters and are increasingly recognised as a cause 
of serious invasive fungal infections (IFIs) in Australia, California and 
the southern USA, and Europe.1-8 L prolificans is the causative agent 
in 1.6% and 0.9% of infections after haematopoetic stem cell trans-
plant and solid organ transplantation (SOT) in the United States, 
respectively.9 Risk factors for these infections vary but include un-
derlying haematological malignancy, SOT, trauma including burns, 
poorly controlled diabetes mellitus and other conditions leading to 
immunodeficiency.4,9 Mortality rates of up to 90% are associated 
with these infections.10 Treatment of invasive infections is challeng-
ing as L prolificans isolates are often pan-drug resistant, with ele-
vated minimum inhibitory concentrations (MICs) against all available 
antifungal agents.2,4,11-15 More than 10 years ago, two relatively 
large studies reported that voriconazole was associated with sur-
vival rates between 44% and 66%16-18 and voriconazole was deemed 
the treatment of choice for invasive L prolificans infections.18-21 
This is supported by a recent review of patients published after 
the preferred option for now, the hope lies with novel antifungals currently under 
development.
K E Y W O R D S
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2000 in which overall mortality was lower in patients who received 
voriconazole compared to treatment with other antifungal agents.10 
Although voriconazole is considered the drug of choice, combination 
therapy, particularly with voriconazole plus terbinafine, is also fre-
quently used to combat these infections.4,10,20 The objective of this 
study was to describe the clinical presentation and outcomes in a 
cohort of 41 patients with invasive L prolificans infections occurring 
between 2008 and 2019 that were documented in the FungiScope® 
Registry.22
2  | METHODS
A retrospective review of medical records of all patients with IFIs caused 
by L prolificans in FungiScope® diagnosed between 01 January 2008 
and 09 September 2019 was performed. FungiScope® is a registry of 
rare IFIs and is currently active in 84 countries.22 All proven and prob-
able infections based on the European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections Cooperative Group 
and the National Institute of Allergy and Infectious Diseases Mycoses 
Study Group (EORTC/MSG) criteria were included in this analysis.23 
Of the 41 patients included, 20 originated from the Mycoses Study 
Group International Prospective Study of Phaeohyphomycosis,24 five 
had been published in a case-series in 2018,4 and a total of six were 
included in a previous review of Scedosporium and Lomentospora infec-
tions.10 Results of the superiority of antifungal combination therapy in 
this study cohort has been published elsewhere.25
Breakthrough infections were classified according to recent 
MSG/European Confederation of Medical Mycology (ECMM) cri-
teria.26 Treatment success was defined as stable disease/partial re-
sponse or complete response, while treatment failure was defined 
as deterioration/progression or failure of antifungal therapy at final 
assessment.27 Infections were determined to be disseminated if 
L prolificans was isolated from blood or two non-contiguous ana-
tomic sites. IFI-related mortality was defined as death due to IFI as 
determined by the FungiScope® registry investigator(s).
Statistical analyses used IBM spss Statistics v26 (IBM Corp.). Age 
and treatment durations were presented as median and interquartile 
range (IQR) in days. Treatment regimens were compared between 
those with treatment success vs treatment failure, 28-day overall 
survival vs mortality, and those with vs without IFI-attributed mor-
tality using two-sided Fisher's exact test. The study protocol and 
all study-related procedures were approved by the University of 
California San Diego (UCSD), CA, USA Institutional Review Board 
(IRB) (Project #181119).
3  | RESULTS
Forty-one patients with invasive L prolificans infection (36 proven, 
5 probable) from 8 different countries were documented in 
FungiScope® registry, including patients from Australia (n = 17), the 
United States (n = 11, including 8 from the University of California 
San Diego), Germany (n = 8), and five other countries with one case 
each. Description of each case including underlying risk factor(s), age, 
source of isolate, MIC’s, antifungal treatment, adjunctive therapy (eg 
surgery), survival t 28 days and outcomes are described (Table S1). 
The majority of patients (66%; 27/41) were diagnosed in 2014 or later. 
Median age of patients was 65 years (IQR 48-69). Haematological/
oncological malignancies were the most frequent underlying dis-
eases and observed in 27 (66%) of patients. Disseminated infection 
was detected in 25 (61%) of patients, 19 (46%) had growth of L pro-
lificans in blood culture, and the lung (18 patients; 44%) was the most 
frequently involved organ. Patient characteristics and outcomes are 
summarised in Table 1.
Most patients (24/41, 59%) were classified as breakthrough 
infections, of which nine (38%) occurred during posaconazole 
prophylaxis (8 suspension, 1 tablet formulation), six (25%) during 
voriconazole prophylaxis, five (21%) during fluconazole prophy-
laxis and one each during prophylaxis with liposomal amphoteri-
cin B (LAmB), micafungin and during empiric antifungal treatment 
with combination LAmB + posaconazole and LAmB + micafungin. 
While there was no significant association between breakthrough 
infection and antifungal treatment response, a trend was observed 
towards higher IFI-attributed mortality in those with breakthrough 
infection (P = .061).
Overall, treatment failure occurred in 23/40 infections receiv-
ing antifungal therapy (58%), and both 28-day overall mortality 
and overall death attributable to L prolificans infection were ob-
served in 51% of patients (21/41) each. Treatment failure (84% 
and 81%) and IFI-attributed mortality (80% and 77%, respectively) 
were highest among patients with disseminated infection and 
those with underlying haematological/oncological malignancy.
Nineteen patients were treated with a terbinafine containing 
regimen (Table 1); most patients (18/19) received terbinafine in com-
bination with other antifungals, the most frequent combination with 
voriconazole + terbinafine (16 of 18). Compared to other antifungal 
regimens, treatment with terbinafine (vast majority used dosages of 
250 mg daily or 250 mg twice daily) was significantly associated with 
higher treatment success overall at final assessment (P = .012), with 
a positive trend also observed for treatment regimens that included 
voriconazole (n = 31; including 16 who received voriconazole + ter-
binafine combination; P = .054). Treatment containing LAmB (n = 15; 
11/15 combination therapy) was associated with both treatment fail-
ure (4/4 with monotherapy and 8/11 with combination therapy failed 
treatment; P = .046) and higher IFI-attributed mortality (P = .043). 
Among those who received treatment with voriconazole but without 
terbinafine, 6/15 (40%) responded to treatment, which was slightly 
lower than the 44% (11/25) treatment response observed for other 
treatments. Only seven patients received voriconazole monotherapy 
(median 22 days, IQR 3-47 days); of those, 4/7 (57%) had treatment 
failure with IFI-attributed mortality within 28 days of diagnosis, 
while 3/7 (43%) survived. Better outcomes were observed in those 
with combination antifungal therapy, and specifically, those receiv-
ing voriconazole + terbinafine combination therapy are described in 
detail elsewhere.25
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Seven patients underwent surgical treatment (Table 1), which 
was significantly associated with higher 28-day survival rates 
(P = .045; 3/4 of those receiving surgery for eye infections and 2/3 
receiving other surgery survived).
4  | DISCUSSION
We analysed clinical characteristics, antifungal treatment and out-
come of 41 patients with invasive L prolificans infections in the 
United States, Australia and Europe. Haematological/oncological 
malignancies were the most frequently observed underlying disease 
(66%), disseminated infection was frequent (61%), the lung was the 
most frequently involved organ (44%), and most patients (59%) were 
classified as breakthrough infections. These findings further con-
firm another recent large survey of L prolificans infections, in which 
63% had underlying haematological/oncological malignancy, 59% 
disseminated infection, and lung was the most frequently involved 
organ (39%) as well.10 Overall, 28-day mortality rates were high with 
more than 50% failing antifungal treatment, similar to previous stud-
ies.1,3,10,17 Mortality rates were highest in patients with underlying 
haematological/oncological malignancies, with more than 80% fail-
ing antifungal treatment, and in those with disseminated infection, 
with 84% failing treatment.
In vitro synergism has been demonstrated for combination anti-
fungal therapy with terbinafine + itraconazole against Mucorales,28 
terbinafine + voriconazole against Fusarium spp29 and terbinaf-
ine + voriconazole against L prolificans,30-32 and it was suggested 
almost 20 years ago that combination therapy with an azole plus ter-
binafine may be a treatment option for these infections.33 However, 
the benefit of terbinafine-based regimens was not significant in the 
recent review of 56 published cases of invasive lomentosporiosis 
(including 5 more recent cases that were also included in this study), 
where voriconazole-based regimens were superior but significance 
was not reached in the subgroups of combination treatment.10 
Previous in vitro studies have shown that while some L prolificans 
isolates are susceptible to voriconazole,34 the majority have high 
MICs to all antifungal agents, including voriconazole, which may 
correlate with treatment failure with voriconazole monotherapy.35 
Clinical studies have demonstrated the superiority of voriconazole-
based treatment regimens for L prolificans infections compared to 
LAmB-based regimens,1,16 a finding that was confirmed in our study. 
Furthermore, recently published data from our cohort25 showed the 
highest treatment success with voriconazole when used in combi-
nation with another antifungal agent. Importantly, 39% of patients 
in our cohort had L prolificans breakthrough infections occurring 
under triazole prophylaxis/empirical therapy, with more than a 
third occurring during voriconazole prophylaxis, further evidence 
that voriconazole alone may be insufficient to prevent or treat in-
fections caused by L prolificans. This study shows for the first time 
that terbinafine-based regimens were significantly associated with 
treatment success and survival and that the treatment response rate 
using voriconazole in combination with terbinafine was twice that 





Female sex 16 (39%)
Age (median, interquartile range) 65 (48-69)
Country case occurred
Australia 17 (41%)
United States 11 (27%)
Germany 8 (20%)
Othera  5 (12%)
Underlying diseases/main risk factors
Haematological/oncological malignancies 27 (66%)
Trauma/surgery 6 (15%)
Solid organ transplantation 3 (7%)
Otherb  5 (12%)
Intensive care unit 6 (15%)
Site(s) of infection
Disseminated infection 25 (61%)
Growth in blood culture 19 (46%)
Lung 18 (44%)
Eye 9 (22%)
Skin/deep soft tissue 5 (12%)
Bone 4 (10%)
Brain/central nervous system 5 (12%)
Breakthrough infection 24 (59%)
Antifungal treatmentc 
Voriconazole ± other antifungals 31/40 (78%)
Terbinafine ± other antifungals 19/40 (48%)
LAmB ± other antifungals 15/40 (38%)
Antifungal combination therapy (vs 
monotherapy)
24/40 (60%)





Progression, deterioration, or failure of 
antifungal treatment
23/40 (58%)
28-d overall mortality 21 (51%)
Death attributable to Lomentospora prolificans 
infection
21 (51%)
aCountries include: Belgium, France, Italy, the Netherlands and Spain 
(each one case) 
bOther includes Burn, chronic granulomatous disease, chronic 
pulmonary disease, chronic cardiovascular disease/obesity and contact 
lenses. 
cThose who survived received antifungal treatment for a median of 
181 d (IQR 47-332 d). 
dFinal response assessment was conducted at a median of 241 d (IQR 
84-335) after diagnosis in those who survived and median 13 d (IQR 
4-35 d) after IFI diagnosis in the deceased (ie final assessment on the 
day of death). 
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of other antifungal regimens. Our study also showed a significant 
survival benefit in those receiving surgery, which was also recently 
shown in children with invasive Scedosporium and Lomentospora 
infections who underwent surgery and received voriconazole.8 
Importantly, the majority of infections in this analysis occurred in 
2014 and later, with outcomes likely influenced by potential changes 
in the epidemiology of lomentosporiosis associated with the rise of 
mould active antifungal prophylaxis and advances in treatment of 
haematological/oncological malignancies. As a result, patients who 
develop lomentosporiosis today may be more immunosuppressed 
than those who developed the infection 20 years ago, a theory that 
is supported by the fact that high mortality rates remained mostly 
unchanged despite the introduction of newer and better tolerated 
antifungals.4,16
In conclusion, L prolificans infections are associated with high 
mortality, particularly in patients with underlying haematological/on-
cological malignancies and those with disseminated infection. While 
combination therapy shows some success in lowering persistently 
high mortality rates, hope lies on novel antifungals that are currently 
being developed, specifically F901318 (Olorofim; F2G), which shows 
excellent activity against L prolificans36 and which is currently being 
evaluated in a Phase 2b open-label study (NCT03583164). Until 
novel drugs are available, our findings suggest that voriconazole or 
terbinafine-based regimens, particularly voriconazole + terbinafine 
combination therapy, could be the preferred choice for the treat-
ment of invasive L prolificans infections.
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